Pipeline
We have a robust and sustainable pipeline with 4 clinical stage assets (EMB-01, EMB-02 , EMB-06 and EMB-09) and more than 10 preclinical stage candidates. Our proprietary FIT-Ig® platform and other technical capabilities enable us to target three strategic oncology areas (tumor targeting, dual checkpoint inhibitors, immune cell engagers) and maintain our strong momentum to advance additional preclinical assets to the clinic.
EMB-02
Preclinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
News
2024-10-11
EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2024-09-04
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
Who We Are
EpimAb Biotherapeutics is a clinical stage biopharmaceutical company with research and manufacturing facilities in Shanghai and Suzhou. With our unique and proprietary platform technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that is able to generate bispecific molecules with antibody-like properties, we are creating a pipeline of novel therapeutics focused around immuno-oncology and other disease areas with high unmet need.
Contact
Shanghai
Adress
6th Floor, Building 2, Jinchuang Building, 702 Zhongke Road, Zhangjiang High-tech Park, Shanghai, 201204, China
Phone
Email
contact@epimab.com
shanghai